Search company, investor...

Founded Year



Series D | Alive

Total Raised


Last Raised

$71M | 3 yrs ago

About Sight Diagnostics

Sight Diagnostics is a company focused on improving health through fast, accurate, and convenient diagnostic testing in the healthcare industry. The company offers a high-performance complete blood count (CBC) analyzer that provides accurate results in minutes, not days, using a sample from a finger prick or venous draw. The primary sectors the company sells to include the healthcare and medical industries. It was founded in 2011 and is based in Tel Aviv, Israel.

Headquarters Location

23 Menahem Begin Street

Tel Aviv, 6618356,



ESPs containing Sight Diagnostics

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Monitoring, Imaging & Diagnostics Tech

The point-of-care blood tests market aims to provide rapid access to lab results for physicians, improving patient outcomes, office efficiency, patient satisfaction, and lowering overall healthcare costs. The market addresses the challenge of delays in working with third-party labs. It also satisfies an urgent need for accurate, rapid, and deployable diagnostic testing that is accessible and affor…

Sight Diagnostics named as Leader among 5 other companies, including Genalyte, IMMUNOSENS, and Truvian.

Sight Diagnostics's Products & Differentiators

    Sight OLO

    AI-based blood diagnostics analyzer that offers lab-grade Complete Blood Count (CBC) results from two drops of blood in minutes. OLO leverages a patented method of “digitizing” blood samples and is built with high-powered microscopes, computer vision, and artificial intelligence, allowing it to deliver lab-quality results in a much more compact and efficient format than traditional CBC machines. The analyzer’s computer vision technology produces over 1,000 highly detailed images of blood from each blood sample and then deploys fully automated AI algorithms to measure, classify, and count the different cells and identify abnormalities, measuring 19 different parameters with 5-part differentials, including full flagging capabilities.


Research containing Sight Diagnostics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sight Diagnostics in 1 CB Insights research brief, most recently on Feb 16, 2022.

Expert Collections containing Sight Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sight Diagnostics is included in 2 Expert Collections, including Artificial Intelligence.


Artificial Intelligence

10,958 items

Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Latest Sight Diagnostics News

Your browser does not support the video tag.

Feb 13, 2023

Life-saving Israeli blood test device sent to quake-struck Turkey Innovative device from Sight Diagnostics requires only two drops of blood, and can deliver results in 10 minutes, to quickly assess severity of injuries and increase survival rates. An aerial view of the staging area of the Israeli army and Israeli rescue forces near the scene of the deadly earthquake in Kahramanmaras, Turkey, on February 9, 2023. Photo by Erik Marmor/Flash90 An innovative Israeli-made device that can speed up blood test diagnosis to improve treatment in the field is in use in Israel’s field hospital in Turkey as the country struggles to cope with the aftermath of the devastating earthquakes. Israeli teams are among many international representatives working to find survivors after two disastrous earthquakes and a series of aftershocks hit Turkey and neighboring Syria, killing more than 33,000 people. Now, Sight Diagnostics’ OLO device is set to help the Israeli rescuers working on the ground to accurately diagnose the general condition of survivors and speed up the provision of appropriate medical treatment to increase the chances of survival. Testing on the ground would allow medical authorities to quickly assess the severity of the injuries, such as internal bleeding, infection, damage to vital organs or any other life-threatening conditions. The OLO analyzer, which is based on AI algorithms, requires only two drops of blood to perform a complete blood count and can deliver test results in the span of 10 minutes. The OLO analyzer can give complete blood results in just 10 minutes. Photo courtesy of Sight Diagnostics The company said OLO’s compact size, roughly the size of a home desktop printer, makes it suitable for use in a wide variety of remote environments, beyond the central laboratory. Sight Diagnostics said the IDF Medical Corps approached the Israeli company, asking it to provide the device to the IDF field hospital located in the disaster area. So far, two devices and hundreds of test kits have been sent to Turkey, with each kit able to analyze a single blood test. “Sight Diagnostics’ mission is to provide better care when and where it is needed by bringing fast and convenient blood diagnostics to the point of care without compromising on accuracy,” said Doron Birger, Interim CEO & Chairman of the Board at Sight Diagnostics. “As much as we wish these situations won’t happen, we are honored to have a small but significant contribution to providing better care to the disaster survivors in Turkey,” he added. The device is also approved for use in the United States by the FDA, where it was cleared for “moderately complex setting.” Sight Diagnostics made headlines two years ago, when it was deployed at John Radcliffe Hospital, part of Oxford University Hospitals NHS Foundation. It allowed staff at the hospital’s emergency departments to determine the likelihood of patients having COVID-19, when the UK was battling the onset of one of its many coronavirus waves. Sight Diagnostics was founded in 2011, and has offices in Israel, the US and the UK. The company’s first product, Parasight ,  was used to diagnose malaria in over 24 countries across the globe. ADVERTISEMENT

Sight Diagnostics Frequently Asked Questions (FAQ)

  • When was Sight Diagnostics founded?

    Sight Diagnostics was founded in 2011.

  • Where is Sight Diagnostics's headquarters?

    Sight Diagnostics's headquarters is located at 23 Menahem Begin Street, Tel Aviv.

  • What is Sight Diagnostics's latest funding round?

    Sight Diagnostics's latest funding round is Series D.

  • How much did Sight Diagnostics raise?

    Sight Diagnostics raised a total of $127.52M.

  • Who are the investors of Sight Diagnostics?

    Investors of Sight Diagnostics include OurCrowd, Longliv Ventures, Koch Disruptive Technologies, New Alliance Capital, Go Capital and 8 more.

  • Who are Sight Diagnostics's competitors?

    Competitors of Sight Diagnostics include SigTuple, OncoHost, Oxford Immune Algorithmics, Noul, PixCell Medical Technologies and 7 more.

  • What products does Sight Diagnostics offer?

    Sight Diagnostics's products include Sight OLO.


Compare Sight Diagnostics to Competitors


iAssay is a company focused on healthcare technology, specifically in the domain of point of care diagnostics. The company offers a handheld device and an open platform for conducting various diagnostic tests, replacing multiple single-function devices. The device is embedded with smart phone technology, allowing for the use of various apps designed for the system, and it securely aggregates and stores test, patient, and wearables data in the cloud for automatic population into patient's electronic medical records. It was founded in 2013 and is based in San Diego, California.

Efemoral Medical

Efemoral Medical provides medical devices and equipment services. The company develops bioresorbable solutions to treat patients with vascular disease. Its product includes Efemoral Vascular Scaffold System (EVSS). It serves clients in the healthcare sector. Efemoral Medical was founded in 2018 and is based in Los Altos, California.

Uh-Oh Labs Logo
Uh-Oh Labs

Uh-Oh Labs offers a disease-testing platform. It develops diagnostic and nucleic acid testing that provides precise and lab-grade results for schools, offices, and individuals. The company was founded in 2018 and is based in Santa Clara, California.

Truvian Logo

Truvian operates as a healthcare company. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. It provides lab-accurate results in less time for a comprehensive suite of health tests. It was formerly known as Salveo Dx. It was founded in 2015 and is based in San Diego, California.

Viva In Vitro

Viva In Vitro focuses on sepsis and other acute inflammatory processes. It develops diagnostics and prognosis compact devices for the diagnosis of abdominal sepsis, prognosis, and patient stratification. The company was founded in 2021 and is based in Murcia, Spain.

ThinkCyte Logo

ThinkCyte focuses on the integration of advanced hardware, machine learning, and biotechnology in the science and healthcare sectors. The company offers a platform that combines traditional fluorescence flow cytometry with high-dimensional morphological profiling and AI to enable label-free cell sorting and unbiased single-cell profiling. It was founded in 2016 and is based in Redwood City, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.